Skip to Main Content

For the first time, a pricey biologic now has more than one lower-cost biosimilar to fend off, a development that should usher in long-awaited savings for the overburdened U.S. health care system.

On Monday, Merck and Samsung Bioepis launched their biosimilar version of Remicade, a blockbuster treatment for rheumatoid arthritis and Crohn’s disease, among other ailments. The launch was sooner than Wall Street expected, but after months of anticipation, we finally know the pricing — a 35 percent discount to the brand-name biologic, which is marketed in the U.S. by Johnson & Johnson.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!